

BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE

May 2-3, 2022



B B H I C 2 0 2 2

“

Bloom Burton & Co. exists to accelerate returns in the healthcare sector for both companies and investors. There is no greater illustration of the power of our platform than this conference, which has grown into Canada’s flagship healthcare investment and networking event over the past decade.

”



WELCOME

Bloom Burton & Co. and its affiliates add value because we have a talented and dedicated team to provide important services to accelerate the growth of companies and returns for investors. We offer investment banking services such as capital raising, M&A advisory, equity research, sales, trading in addition to our scientific and business advisory work. Across the continuum of value-added services, we have direct investment capabilities by offering equity and debt funds to interested investors and we also help form and grow – in partnership with others – entirely new companies. You can see them present at this very conference and they include: Triumvira Immunologics, Grey Wolf Animal Health, Satellos Bioscience and Appili Therapeutics, for example.

We had our fifth edition of the Bloom Burton Award Gala last September and it has now cemented itself as the preeminent award to celebrate each year's most important contributor in the Canadian healthcare sector. We hope to see you all at the 2022 Bloom Burton Award Gala, in person, on September 29, 2022 at the Four Seasons Hotel in Toronto. Our three finalists for this year's award will also be announced this week!

We are humbled to serve as the central catalyst for our industry and we are so proud of our team, who work tirelessly to serve our clients. We strive to produce exceptional deliverables and outcomes and we are here for you as you make new connections and plan for the success of the healthcare sector in Canada and beyond.

Have a wonderful conference!

Brian and Jolyon and the entire team

CONTENT

3 About

4 Agenda

6 Keynote Speaker

8 Panelists - Investing in Commercial-Stage
Healthcare Companies

11 Panelists - Investing in R&D-Stage Healthcare
Companies

16 Presenting Companies

54 About Bloom Burton & Co.

58 Sponsors

60 Conference Information



Network Name
Bloom Burton & Co.

Access Code
BBHIC2022

ABOUT

Bloom Burton & Co. Healthcare Investor Conference

Bloom Burton & Co.'s annual Healthcare Investor Conference takes place at the Metro Toronto Convention Centre (North Building) on May 2-3, 2022.

Approximately 66 of Canada's premier publicly traded and venture sponsored private companies are invited to present to our audience, while hundreds of Canadian, U.S. and international investors attend to hear the latest developments in the Canadian healthcare industry.

Investors also have the opportunity participate in our 1-on-1 meeting system with company management. We also provide a stage for world renowned keynote speakers and investor panelists, who describe the ups and downs of the markets and the state of the global healthcare industry.



AGENDA

Monday, May 2, 2022

8:30AM Opening Remarks and TSX Opening			
Plenary Room 106/107			
	Hall C/D	Hall B	Hall A
9:30AM	AbCellera Biologics Biotechnology NASDAQ: ABCL	Intelliject Surgical Medical Technology PRIVATE	DRI Healthcare Trust Specialty Pharmaceutical TSX: DHT.UN, TSX: DHT.U
10:00AM	Chinook Therapeutics Biotechnology NASDAQ: KDNV	Conavi Medical Medical Technology PRIVATE	HLS Therapeutics Specialty Pharmaceutical TSX: HLS
10:30AM	Bellus Health Biotechnology TSX: BLU, NASDAQ: BLU	Synaptive Medical Medical Technology PRIVATE	Knight Therapeutics Specialty Pharmaceutical TSX: GUD
11:00AM	Field Trip Health Biotechnology TSX: FTRP, NASDAQ: FTRP	Icentia Medical Technology PRIVATE	Miravo Healthcare Specialty Pharmaceutical TSX: MRV
11:30AM	Microbix Biosystems Biotechnology TSX: MBX	Kardium Medical Technology PRIVATE	Medexus Pharmaceuticals Specialty Pharmaceutical TSX: MDP
12:00PM Lunch and Keynote Speaker			
PETER KOLCHINSKY Plenary Room 106/107			
1:30PM	Repare Therapeutics Biotechnology NASDAQ: RPTX	Hamilton Thorne Medical Technology TSXV: HTL	CareRx Healthcare Services/Digital Health TSX: CRRX
2:00PM	Zymeworks Biotechnology NYSE: ZYME	Profound Medical Medical Technology TSX: PRN, NASDAQ: PROF	Notch Therapeutics Biotechnology PRIVATE
2:30PM	ESSA Pharma Biotechnology NASDAQ: EPIX	OpSens Medical Technology TSX: OPS	Virica Biotech Tools PRIVATE
3:00PM	Medicenna Therapeutics Biotechnology TSX: MDNA, NASDAQ: MDNA	Perimeter Medical Imaging Medical Technology TSXV: PINK	Nicoya Lifesciences Tools PRIVATE
3:30PM	Fusion Pharmaceuticals Biotechnology NASDAQ: FUSN	Titan Medical Medical Technology TSX: TMD, NASDAQ: TMDI	Avivagen Biotechnology TSXV: VIV
4:00PM	Point Biopharma Biotechnology NASDAQ: PNT	Neovasc Medical Technology TSX: NVCN, NASDAQ: NVCN	LQT Therapeutics Biotechnology PRIVATE
5:00PM Cocktail Reception			
Steam Whistle Brewing at 255 Bremner Blvd			

AGENDA

Tuesday, May 3, 2022

8:30AM Investing in Commercial-Stage Healthcare Companies Panel RODNEY ALTMAN, EMILY JANVEY, MARK JELLEY, AND DANIELLA KRANJAC Plenary Room 106/107			
	Hall C/D	Hall B	Hall A
9:30AM	dentalcorp Healthcare Services/ Digital Health TSX: DNTL	Congruence Therapeutics Biotechnology PRIVATE	IntelGenx Specialty Pharmaceutical TSX: IGX
10:00AM	WELL Health Technologies Healthcare Services/ Digital Health TSX: WELL	Triumvira Immunologics Biotechnology PRIVATE	BioSyent Specialty Pharmaceutical TSXV: RX
10:30AM	LifeSpeak Healthcare Services/ Digital Health TSX: LSPK	KisoJi Biotechnology Biotechnology PRIVATE	Crescita Therapeutics Specialty Pharmaceutical TSX: CTX
11:00AM	The Fertility Partners Healthcare Services/ Digital Health PRIVATE	Oncolytics Biotech Biotechnology TSX: ONC, NASDAQ: ONCY	Valeo Pharma Specialty Pharmaceutical CSE: VPH
11:30AM	AlayaCare Healthcare Services/ Digital Health PRIVATE	Xenon Pharmaceuticals Biotechnology NASDAQ: XENE	Grey Wolf Animal Health Specialty Pharmaceutical PRIVATE
12:00PM Lunch and Investing in R&D-Stage Healthcare Companies Panel CHRISTIANA BARDON, ARJUN GOYAL, DION MADSEN, AND MICHELLE ROSS Plenary Room 106/107			
1:30PM	VitalHub Healthcare Services/Digital Health TSX: VHI	Theratechnologies Biotechnology TSX: TH, NASDAQ: THTX	ARTMS Medical Technology PRIVATE
2:00PM	CloudMD Software & Services Healthcare Services/ Digital Health TSXV: DOC	Antibe Therapeutics Biotechnology TSX: ATE	Searchlight Pharma Specialty Pharmaceutical PRIVATE
2:30PM	Think Research Healthcare Services/Digital Health TSXV: THNK	Satellos Bioscience Biotechnology TSXV: MSCL	Verity Pharmaceuticals Specialty Pharmaceutical PRIVATE
3:00PM	Newtopia Healthcare Services/ Digital Health TSXV: NEWU	Appili Therapeutics Biotechnology TSX: APLI	Methapharm Specialty Pharmaceutical PRIVATE
3:30PM	NeuPath Health Healthcare Services/ Digital Health TSXV: NPTH	Fibrocor Therapeutics Biotechnology PRIVATE	FORUS Therapeutics Specialty Pharmaceutical PRIVATE
4:00PM	Felix Health Healthcare Services/ Digital Health PRIVATE	Inversago Pharma Biotechnology PRIVATE	Enhanced Medical Nutrition Specialty Pharmaceutical PRIVATE

KEYNOTE SPEAKER

Monday, May 2, 2022 | 12:30PM - 1:30PM
Plenary Room 106/107



Keynote Speaker Information

Peter Kolchinsky

Managing Partner, RA Capital Management

Peter Kolchinsky is a Founder of and a Managing Partner at RA Capital Management. He is active in both public and private investments in companies developing drugs, medical devices, diagnostics and research tools, and serves as a board member for various public and privately-held companies.

Peter served on the Board of Global Science and Technology for the National Academy of Sciences and is the author of “The Great American Drug Deal” and “The Entrepreneur’s Guide to a Biotech Startup”.

Peter also founded the not-for-profit, No Patient Left Behind to advocate for healthcare reforms that would solve affordability issues and promote continued biomedical innovation.

INVESTING IN COMMERCIAL-STAGE HEALTHCARE COMPANIES PANEL

Tuesday, May 3, 2022 | 8:30AM - 9:30AM
Plenary Room 106/107

- 
- Rodney Altman**
Wells Fargo Strategic Capital
 - Emily Janvey**
ICONIQ Capital
 - Mark Jelley**
OrbiMed Advisors
 - Daniella Kranjac**
Dynamk Capital

Panelists - Investing in Commercial-Stage Healthcare Companies

**Rodney Altman**

Managing Director
Wells Fargo
Strategic Capital

Rodney Altman is a venture capital and private equity healthcare investor with over twenty years of experience. Rod has been a Managing Director at Wells Fargo Strategic Capital since 2019. He has served on numerous boards and currently is a director on the boards of Array Behavioral Health, Mangrove Physician Partners, and ConcertoCare.

Rod continues to practice emergency medicine at Stanford and Kaiser on a limited basis. Originally from Montreal, Rod now resides in San Francisco with his young son.

Emily Janvey is the Health Care Sector Head within the Investment Strategy Group at ICONIQ Capital. She leads coverage for Health Care across asset classes. Prior to joining ICONIQ, Emily was a Director on KKR's America's Health Care Private Equity team investing across the health care landscape and with a focus on large cap private equity, growth equity and non-dilutive financings. Emily was previously a vice president at Sixth Street Partners where she provided alternative financing to pharma and biotech. Emily began her career at McKinsey and Company consulting across health care verticals.

Emily has served on the Boards of Directors of companies across health care sectors and stages, including Global Medical Response, Arbor Pharmaceuticals, and Headlands Research.

**Emily Janvey**

Director,
Healthcare Sector
Head
ICONIQ Capital

Panelists - Investing in Commercial-Stage Healthcare Companies



Mark R. Jelley is a Partner on the Credit and Royalty team at OrbiMed Advisors, focused on structured finance and royalty investments across healthcare sectors.

Prior to joining OrbiMed, he was an Associate in investment banking at UBS focused on leveraged finance transactions. Prior to UBS, Mark was an analyst at Macquarie Capital, focused on principal investments.

Mark Jelley**Partner****OrbiMed Advisors**

Daniella Kranjac is Founding Partner at Dynamk Capital, uniquely focused on Life Science Industrials - the tools, technologies and services that enable the discovery, development and production of life-saving therapies and deliver on the biopharmaceutical industry's evolution towards lower costs, and increased access to medicines globally.

Daniella has deep domain experience in life sciences as an entrepreneur, corporate executive, advisor and investor. Prior to Dynamk Capital, she was CEO and Founder of Dynamk Consulting, providing strategy and business development consulting to leading life science companies and startups. She began her career as a Co-Founder of Wave Biotech where she drove the growth of a disruptive technology, building the company and leading the group to a successful exit and acquisition by GE Healthcare in 2007.

Daniella currently serves on the boards of Envisagenics, RoosterBio, Virica Biotech and Xcell Biosciences.

**Daniella Kranjac****Founding Partner,
Managing Director
Dynamk Capital**

INVESTING IN R&D-STAGE HEALTHCARE COMPANIES PANEL

Tuesday, May 3, 2022 | 12:30PM - 1:30PM

Plenary Room 106/107

- **Christiana Bardon**
MPM Capital
- **Arjun Goyal**
Vida Ventures
- **Dion Madsen**
Amplitude Venture Capital
- **Michelle Ross**
Sphera Funds Management

Panelists - Investing in R&D-Stage Healthcare Companies



Christiana (Chris) Bardon is Co-Managing Partner of BioImpact Capital, an affiliate manager of MPM Capital and leads MPM's public market investing as portfolio manager for BioImpact Equities (f/k/a Burrage Capital) and the Oncology Impact Funds.

Previously, Chris was a healthcare analyst at Fidelity Investments covering biotechnology, life-science tools and diagnostics, and she started her career as an analyst at MPM. She currently serves on the Harvard Medical School Board of Fellows and is a Trustee of the American Association for Cancer Research Foundation.

Christiana Bardon

Portfolio Manager
MPM Capital

Arjun Goyal is a Co-Founder and Managing Director of Vida Ventures, a leading US-based life sciences venture capital firm with approximately \$1.7 billion in AUM. Arjun focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Before co-founding Vida Ventures in 2017, Arjun was a life sciences investor at 5AM Ventures.

Arjun serves as a director on the boards of Scorpion Therapeutics, Quanta Therapeutics, Affini-T, Alterome Therapeutics and Centessa Pharmaceuticals and has played key roles in Vida Venture's investments in Homology Medicines, Pionyr Immunotherapeutics, Peloton Therapeutics, and Asklepios Bio.

Arjun has received multiple awards for his work including the Advance Award for Technology & Entrepreneurship from the Australian Government. He is a co-inventor on one patent and had served on the editorial board of an international scientific journal. He serves on the Committee for the American Australian Association Education Fellowship.

**Arjun Goyal**

Co-Founder,
Managing Director
Vida Ventures

Panelists - Investing in R&D-Stage Healthcare Companies



Dion Madsen
Founding Partner
Amplitude Venture
Capital

Dion Madsen is a Founding Partner at Amplitude Venture Capital, a firm focused on building world-class Canadian companies in precision medicine and next-generation medical devices. They are currently investing from a \$200M fund and also managing BDC Capital's Healthcare Venture Fund where he was Senior Managing Partner.

Prior to joining BDC, Dion was Co-Founder of Physic Ventures and focused on opportunities in health delivery, chronic disease care and prevention and he also was Managing Director of the investment practice of Unilever Technology Ventures. From 1998 to 2003, Dion served as a Partner of RBC Capital Partners, the private equity arm of the Royal Bank of Canada and from 2004-2005 he worked at Chiron Corporation as Head of Investor Relations and also worked in corporate development.

Dion holds the Chartered Financial Analyst designation and has served as a mentor in the Kauffman Fellows Program.

Michelle Ross is the Portfolio Manager at Sphera Healthcare having joined the firm in 2016 and is located in the New York office. In April 2018, she helped launch Sphera's Biotech Fund focused on small and mid-cap equity investments.

Prior to joining Sphera, Michelle spent three years at PointState Capital as Vice President covering the healthcare sector. From 2006 to 2013, Michelle was an analyst at Soros Fund Management where she specialized in global healthcare investments.



Michelle Ross
Portfolio Manager,
Partner
Sphera Funds
Management

#BBHIC2022

BLOOM BURTON & CO.
HEALTHCARE INVESTOR CONFERENCE

COCKTAIL

Reception

May 2, 2022 | 5:00PM

Steam Whistle Brewing

255 Bremner Blvd.

Toronto, Ontario

M5V 3M9



BBHIC 2022

PRESENTING COMPANIES

This year's Bloom Burton & Co. Healthcare Investor Conference hosts approximately 66 of Canada's premier publicly-traded and venture-backed private companies as well as promising pre-venture companies in the healthcare industry from the following sectors:

Biotechnology
Healthcare Services/Digital Health
Medical Technology
Specialty Pharmaceutical
Tools



Biotechnology

NASDAQ: ABCL

AbCellera Biologics

Monday, May 2, 2022 | 9:30AM ET
HALL C/D



AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera's full-stack, AI-powered drug discovery platform integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development.

Healthcare Services/Digital Health

PRIVATE

AlayaCare

Tuesday, May 3, 2022 | 11:30AM ET
HALL C/D



AlayaCare offers an end-to-end software platform for home and community care providers to manage the entire client lifecycle from referrals and intake to billing, payroll and beyond. Combining traditional in-home and virtual care solutions, AlayaCare enables care providers across the world to propel towards innovation and healthcare of the future. AlayaCare was founded in 2014 and is the parent company of Procura, Arrow, CIMS, and AcuteNet.

Biotechnology**TSX: ATE****Antibe Therapeutics****Tuesday, May 3, 2022 | 2:00PM ET****HALL B**

Antibe is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The Company's current pipeline includes assets that seek to overcome the gastrointestinal ("GI") ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs ("NSAIDs"). Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today's NSAIDs for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company's anticipated next target is inflammatory bowel disease ("IBD"), a condition long in need of safer, more effective therapies.

Biotechnology**TSX: APLI****Appili Therapeutics****Tuesday, May 3, 2022 | 3:00PM ET****HALL B**

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection.

Medical Technology**PRIVATE****ARTMS****Tuesday, May 3, 2022 | 1:30PM ET****HALL A**

Based in Burnaby, British Columbia, Canada, ARTMS Inc. is a global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world's most-used diagnostic imaging isotopes. ARTMS' flagship product, the QUANTM Irradiation System™ (QISTM), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry.

Biotechnology**TSXV: VIV****Avivagen****Monday, May 2, 2022 | 3:30PM ET****HALL A**

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. The company is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada.

Biotechnology**TSX: BLU, NASDAQ: BLU****Bellus Health**

Monday, May 2, 2022 | 10:30AM ET
HALL C/D



BELLUS Health Inc. is a clinical stage pharmaceutical company focused on developing a P2X3 antagonist to address chronic cough and other hypersensitization disorders. The Company's lead candidate, BLU-5937, is a highly selective P2X3 antagonist currently being developed for the treatment of chronic cough. The Company plans to initiate Phase 3 registration trials in the second half of 2022. BELLUS Health is also exploring how inhibition of P2X3 receptors can help treat other afferent hypersensitization-related disorders.

Specialty Pharmaceutical**TSXV: RX****BioSyent**

Tuesday, May 3, 2022 | 10:00AM ET
HALL A



BioSyent is a profitable, growth-oriented, specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.

BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

Medical Technology

PRIVATE

Canary Medical



Canary Medical was conceived and created by a team of medical device developers with active implantable experience, clinician guidance, and IoT experts with the vision that (1) healthcare transformation requires better and cheaper healthcare data, (2) better monitoring and better data will produce better outcomes at (3) lower costs. Canary Medical's patented implant and data management ecosystem technology provides benefits to all stakeholders, patients, clinicians, HCPs and payors. Canary Medical is led by a team of experienced entrepreneurs, researchers and data scientists globally regarded for their expertise in medical device design, development and data informatics.

Healthcare Services/Digital Health

TSX: CRRX

CareRx

Monday, May 2, 2022 | 1:30PM ET
HALL A



CareRx is Canada's leading provider of pharmacy services to seniors living communities. We serve over 96,000 residents in over 1,600 seniors and other congregate care communities (long-term care homes, retirement homes, assisted living facilities, and group homes). We are a national organization with a large network of pharmacy fulfillment centres strategically located across the country. This allows us to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. We use best-in-class technology that automates the preparation and verification of multi-dose compliance packaging of medication, providing the highest levels of safety and adherence for individuals with complex medication regimens. We take an active role in working with our home operator partners to promote resident health, staff education, and medication system quality and efficiency.

Biotechnology**NASDAQ: KDNY****Chinook Therapeutics****Monday, May 2, 2022 | 10:00AM ET****HALL C/D**

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.

Healthcare Services/Digital Health**TSXV: DOC****CloudMD Software & Services****Tuesday, May 3, 2022 | 2:00PM ET****HALL C/D**

CloudMD is transforming the delivery of healthcare. We combine our patient-centric approach with an advanced technology platform that connects all points of a patient's healthcare journey and provides better access to care and improved outcomes. CloudMD's proprietary technology delivers continuity of care through hybrid primary care clinics, specialists, telemedicine, mental health support, healthcare navigation, educational resource, and artificial intelligence (AI).

Medical Technology**PRIVATE****Conavi Medical**

Monday, May 2, 2022 | 10:00AM ET
HALL B



Conavi Medical Inc., is a privately-held company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. The Company's patented hybrid intravascular imaging system is the first and only of its kind to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. Conavi is focused on driving adoption of its advanced imaging solution.

Biotechnology**PRIVATE****Congruence Therapeutics**

Tuesday, May 3, 2022 | 9:30AM ET
HALL B



Congruence Therapeutics is a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. Using structural bioinformatics, computational chemistry, and machine learning, the Company is deploying an in silico platform that enables the design of new pharmacological stabilizers, a validated class of small molecules, at an unprecedented speed and scale.

Specialty Pharmaceutical**TSX: CTX****Crescita Therapeutics****Tuesday, May 3, 2022 | 10:30AM ET****HALL A****CR**  **SCITA**
T H E R A P E U T I C S

Crescita is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin.

Healthcare Services/Digital Health**TSX: DNTL****dentalcorp****Tuesday, May 3, 2022 | 9:30AM ET****HALL C/D** dentalcorp

dentalcorp is Canada's largest and fastest growing network of dental practices, committed to advancing the overall well-being of Canadians by delivering the best clinical outcomes and unforgettable experiences. dentalcorp acquires leading dental practices, uniting them in a common goal: to be Canada's most trusted healthcare network. Leveraging its industry-leading technology, know-how and scale, dentalcorp offers professionals the unique opportunity to retain their clinical autonomy while unlocking their potential for future growth.

Specialty Pharmaceutical

TSX: DHT.UN, TSX: DHT.U

DRI Healthcare Trust

Monday, May 2, 2022 | 9:30AM ET

HALL A



DRI Healthcare Trust provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Our business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties with the aim to deliver attractive growth in cash royalty receipts over the long term. DRI Healthcare Trust is an unincorporated open-ended trust governed by the laws of the Province of Ontario, externally managed by its manager, DRI Capital Inc.

Specialty Pharmaceutical

PRIVATE

Enhanced Medical Nutrition

Tuesday, May 3, 2022 | 4:00PM ET

HALL A



Enhanced Medical Nutrition Inc. develops innovative medical nutrition products to help patients prepare better and recover faster from surgery. These products, referred to as enteral formulations, are powders, reconstituted in water and taken as a drink or tube feed. Similar to a marathon, preparing for a surgical procedure requires a logical approach, addressing deficiencies that lead to a significant impact on individual outcomes and healthcare system economics. EMN is focused in supporting surgical oncology, cardiac surgery, and outpatient orthopaedic surgery. EMN has a product commercialization pipeline that includes proprietary products that improve wound healing and weight management, supporting a patient's journey leading up to and following surgery.

Biotechnology

NASDAQ: EPIX

ESSA Pharma

Monday, May 2, 2022 | 2:30PM ET

HALL C/D

The logo for ESSA Pharma, featuring the word "ESSA" in a bold, blue, sans-serif font. The letter "A" is stylized with a small orange dot above its right vertical stroke.

ESSA is a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer. ESSA's lead clinical candidate, EPI-7386, represents a new approach to disrupting androgen receptor signaling pathway, the primary driver of prostate cancer growth.

Healthcare Services/Digital Health

PRIVATE

Felix Health

Tuesday, May 3, 2022 | 4:00PM ET

HALL C/D

The logo for Felix Health, featuring the word "felix" in a lowercase, orange, sans-serif font.

Founded in 2019, Felix is a patient-driven digital healthcare company empowering people to take control of their health and wellbeing. We're passionate about building technology and beautiful product experiences to make healthcare more accessible (and maybe even more enjoyable) for all Canadians. Felix is one of Canada's leading end-to-end healthcare platforms, providing online diagnoses, prescription delivery, and ongoing care for birth control, erectile dysfunction, acne, hair loss, herpes, and more.

Biotechnology**PRIVATE****Fibrocor Therapeutics****Tuesday, May 3, 2022 | 3:30PM ET
HALL B**

Fibrocor is using its differentiated target identification and validation platform to discover precision medicines for fibrosis, with proprietary access to kidney, lung and liver biobanks and longitudinal data. The first small molecule discovered using this platform should enter clinical trials in 2022, with two more programs advancing towards IND-enabling studies and a number of other target programs currently in various stages of development. The company has a partnership with Galapagos NV (NASDAQ: GLPG) as well as proprietary Fibrocor programs under development. Fibrocor is privately held, funded by strategic investors (Galapagos and Evotec) and a prominent European venture fund. Fibrocor is seeking to raise a Series A round in 2022.

Biotechnology**TSX: FTRP, NASDAQ: FTRP****Field Trip Health****Monday, May 2, 2022 | 11:00AM ET
HALL C/D**

Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics and our Field Trip Health division building centres for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we seek to help people in need with a simple, evidence-based way to heal and heighten engagement with the world.

Specialty Pharmaceutical**PRIVATE****FORUS Therapeutics****Tuesday, May 3, 2022 | 3:30PM ET****HALL A**

FORUS Therapeutics is a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer. Our mission is to bring solutions to cancer patients, caregivers, physicians and our partners by accelerating unique and important treatments that meaningfully enhance life.

Biotechnology**NASDAQ: FUSN****Fusion Pharmaceuticals****Monday, May 2, 2022 | 3:30PM ET****HALL C/D**

At Fusion, we are pushing the boundaries of science to create innovative precision medicines for cancer.

We are a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear™ linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the therapies to tumors.

We believe our proprietary Fast-Clear™ linker technology is a safer approach to targeted radiopharmaceuticals. Fast-Clear™ represents a revolutionary step towards developing safe and effective new radiotherapeutics as the standard of care for the treatment of multiple tumor types.

We believe this evolution of radiopharmaceuticals holds great promise to improve the lives of patients with cancer.

Specialty Pharmaceutical**PRIVATE****Grey Wolf Animal Health****Tuesday, May 3, 2022 | 11:30AM ET****HALL A**

Grey Wolf Animal Health (“Grey Wolf”) was founded by a veterinarian to bring to market products that meet the unmet needs of veterinarians, pets and clinics across Canada. In 2018, Grey Wolf completed a strategic acquisition of a full-scale animal health company with a nationwide commercial footprint. Since then, Grey Wolf has launched five product portfolios and driven growth in our established brands through our integrated sales and marketing approach targeting veterinarians and pet owners across Canada. Last year, Grey Wolf completed a second strategic acquisition of Trutina Pharmacy, a compounding pharmacy focused on the equine market. Today, Grey Wolf commercializes a broad portfolio of products including pharmaceuticals, nutraceuticals and consumables, to veterinarians and clinics across Canada for the health and wellbeing of companion animals and equines. Grey Wolf recently announced a definitive agreement related to a reverse take-over and expects to be publicly traded by the end of the summer. We are committed to improving the quality of life for animals and those who care for them.

Medical Technology**TSXV: HTL****Hamilton Thorne****Monday, May 2, 2022 | 1:30PM ET****HALL B**

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, IVFtech, Embryotech Laboratories, and Tek-Event brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Specialty Pharmaceutical**TSX: HLS****HLS Therapeutics****Monday, May 2, 2022 | 10:00AM ET****HALL A**

HLS Therapeutics®

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.

Medical Technology**PRIVATE****Icentia****Monday, May 2, 2022 | 11:00AM ET****HALL B****icentia™**

Based in Canada, Icentia is a combined medical device and service company. Icentia pioneers innovative solutions for healthcare institutions in the field of medical testing. Icentia aims to help healthcare institutions in becoming more efficient while providing patients with the ease, comfort, peace of mind and safety of reliable at-home medical monitoring through technological advances.

Specialty Pharmaceutical**TSX: IGX****IntelGenx****Tuesday, May 3, 2022 | 9:30AM ET****HALL A**

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx's superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions. IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.

Medical Technology**PRIVATE****Intellijoint Surgical****Monday, May 2, 2022 | 9:30AM ET****HALL B**

Intellijoint Surgical® develops and commercializes surgical planning & navigation solutions for total hip and knee joint replacements, as well as digital patient engagement for all orthopaedic specialties. It is committed to improving patients' lives by providing every surgeon with effective, easy-to-use technology to manage the entire episode of care. Intellijoint's technology is used by top orthopaedic institutions and surgeons globally.

Biotechnology**PRIVATE****Inversago Pharma**

Tuesday, May 3, 2022 | 4:00PM ET

HALL B

Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), Obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).

Medical Technology**PRIVATE****Kardium**

Monday, May 2, 2022 | 11:30AM ET

HALL B

Kardium Inc. is a rapidly growing medical solutions company that has developed an advanced system for the treatment of atrial fibrillation (AF), which affects more than 59 million people worldwide. The Globe® Mapping and Ablation System is the most complete solution for AF, offering single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation – all in a single catheter. Founded in 2007 and headquartered in Vancouver, Canada, Kardium has been recognized as a top company to work for in BC, including recognition as Medical Technology Company of the Year in 2015 and 2021 by LifeSciences BC.

Biotechnology**PRIVATE****KisoJi Biotechnology**

Tuesday, May 3, 2022 | 10:30AM ET

HALL B

KisoJi

KisoJi is an antibody company that is revolutionizing the discovery and development of antibody therapeutics. Its antibody platform includes multi-species single domain antibody transgenic mice, AI-enabled antibody paratope fingerprinting and search capabilities, and a toolkit to create robust, easily manufacturable multi-specific antibodies. From this platform, the Company has developed a preclinical pipeline that includes tri-specific immune-oncology antibodies for both solid and hematologic cancers, as well as a naked TROP2 antibody with significant single agent anti-tumor effects, including tumor regression, in solid tumor models without the need for a drug conjugate.

Specialty Pharmaceutical**TSX: GUD****Knight Therapeutics**

Monday, May 2, 2022 | 10:30AM ET

HALL A

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM.

Healthcare Services/Digital Health**TSX: LSPK****LifeSpeak****Tuesday, May 3, 2022 | 10:30AM ET****HALL C/D**

LifeSpeak is a leading software-as-a-service provider of a platform for mental health and total wellbeing education for organizations committed to taking care of their employees and customers. With 17+ years of experience creating and curating thousands of expert-led micro-learning videos and other digital content, LifeSpeak's proprietary library's depth and breadth of easily consumable content helps companies around the world support their people anytime and anywhere. LifeSpeak serves a diverse global client base across many industries and sectors, including Fortune 500 companies, government agencies, insurance providers, and other health technology firms. LifeSpeak is the parent company of LIFT Digital Inc. ("LIFT" or "LIFT session"), ALAViDA Health Ltd. ("ALAViDA"), EnCompass Education Solutions ("Torchlight) and Wellbeats Inc. ("Wellbeats).

Biotechnology**PRIVATE****LQT Therapeutics****Monday, May 2, 2022 | 4:00PM ET****HALL A**

LQT Therapeutics, Inc. is pioneering a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias based on research from Beth Israel Deacons Medical Center, Massachusetts General Hospital, and Sanofi, S.A. By combining leading-edge cardiovascular genetics and diagnostics with recent advances in the understanding of the role of SGK1, LQT Therapeutics seems to make meaningful difference in the lives of people suffering from Long QT Syndrome and resistant cancers. Launched in 2019 by the Fonds de solidarité FTQ. LQT Therapeutics was founded by world-class experts in cardiovascular disease, cardiac muscle biology and drug development.

Specialty Pharmaceutical**TSX: MDP****Medexus Pharmaceuticals****Monday, May 2, 2022 | 11:30AM ET****HALL A**

Medexus Pharmaceuticals Inc. is a leading innovative and rare disease pharmaceutical company with a focus on the therapeutic areas of rheumatology, auto-immune disease, specialty oncology, allergy, and pediatric diseases.

We provide market-leading prescription and over the counter brands to patients and healthcare professionals, which we believe greatly enhances quality of life and promotes a healthy lifestyle.

We have a strong North American commercial platform and we currently operate through two unique segments: Medexus Pharma Canada and Medexus Pharma USA.

Biotechnology**TSX: MDNA, NASDAQ: MDNA****Medicenna Therapeutics****Monday, May 2, 2022 | 3:00PM ET****HALL C/D**

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna's early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically "cold" tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

Specialty Pharmaceutical**PRIVATE****Methapharm****Tuesday, May 3, 2022 | 3:00PM ET****HALL A**

Methapharm is a privately held specialty pharmaceutical company that focuses on the acquisition, licensing, and promotion of healthcare products in North America. Methapharm markets its own proprietary products as well as partners with global companies in order to deliver a line of products in the USA and Canada.

Biotechnology**TSX: MBX****Microbix Biosystems****Monday, May 2, 2022 | 11:30AM ET****HALL C/D**

Microbix Biosystems Inc. develops and commercializes proprietary biological and technological solutions for human health and wellbeing. We manufacture a wide range of critical biological materials for the global diagnostics industry, notably antigens used in immunoassays and Quality Assessment and Proficiency (QAPs™) testing products. Microbix's business of producing high quality viral and bacterial preparations are the result of nearly three decades of experience in the field, including strain selection, reliable and efficient organism culture at scale, purification and methods of inactivation. As a result of Microbix's expertise, its products have received widespread and longstanding customer acceptance, with continuing growth in demand. Microbix's current catalogue of biological preparations covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually-transmitted and insect-borne diseases.

The company also applies its biological expertise to develop other innovative and proprietary technologies and products. Its development project pipeline currently includes Kinlytic® Urokinase, a biologic thrombolytic drug used to treat blood clots.

Specialty Pharmaceutical**TSX: MRV****Miravo Healthcare****Monday, May 2, 2022 | 11:00AM ET****HALL A**

Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company's products target several therapeutic areas, including pain, allergy, neurology and dermatology. The Company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo's head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company's manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S., Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration.

Medical Technology**TSX: NVCN, NASDAQ: NVCN****Neovasc****Monday, May 2, 2022 | 4:00PM ET****HALL B**

Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is under clinical investigation in the United States and has been commercially available in Europe since 2015, and Tiara™ for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe.

Healthcare Services/Digital Health**TSXV: NPTH****NeuPath Health****Tuesday, May 3, 2022 | 3:30PM ET****HALL C/D**

NeuPath is a vertically integrated health care provider utilizing research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by chronic pain, spinal injuries, sport-related injuries, and concussions. With equity ownership in seventeen clinics in Ontario and Alberta, NeuPath is building out a large-scale network to better serve patients across Canada and the United States. NeuPath is focused on transforming the hope of a better life into the reality of a life more fully lived.

Healthcare Services/Digital Health**TSXV: NEWU****Newtopia****Tuesday, May 3, 2022 | 3:00PM ET****HALL C/D**

Newtopia is a tech-enabled habit change provider focused on disease prevention and reducing the cost of care for risk-bearing entities like large, self-insured employers. As a provider of whole person care, we prevent, slow and reverse the progression of chronic disease while enriching mental health, resilience and overall human performance. Newtopia's programs leverage genetic, social and behavioral insights to create individualized prevention programs with a focus on type-2 diabetes, heart disease, stroke and weight. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science. Newtopia delivers sustainable clinical and financial outcomes. The company serves some of the largest nationwide employers and health plans.

Tools**PRIVATE****Nicoya Lifesciences****Monday, May 2, 2022 | 3:00PM ET****HALL A**

Nicoya is a Canadian life sciences tools company specializing in innovative biosensor technology for the academic, biotechnology and pharmaceutical sectors. In their mission to improve human life, Nicoya provides scientists with user-friendly and integrated solutions that accelerate label-free biomolecular analysis. With their world-class expertise in nanotechnology and microfluidics, Nicoya is now helping hundreds of scientists succeed in over 50 countries.

Biotechnology**PRIVATE****Notch Therapeutics****Monday, May 2, 2022 | 2:00PM ET****HALL A**

Notch Therapeutics is developing a pipeline of cellular immunotherapies originating from proprietary pluripotent stem cells that are specifically engineered to address the underlying biology of complex disease systems.

The company has unlocked the ability for large-quantity production of T cells and other cells from any source of stem cells to bring best-in-class cell therapies for cancer and other immune disorders to thousands of patients.

Notch is a privately held biotechnology company with headquarters in Vancouver, British Columbia and additional operations in Toronto, Ontario and Seattle, Washington.

Biotechnology**TSX: ONC, NASDAQ: ONCY**

Oncolytics Biotech**Tuesday, May 3, 2022 | 11:00AM ET****HALL B**

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer.

Medical Technology**TSX: OPS**

OpSens**Monday, May 2, 2022 | 2:30PM ET****HALL B**

OpSens focuses mainly in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 150,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada. OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

Medical Technology**TSXV: PINK****Perimeter Medical Imaging****Monday, May 2, 2022 | 3:00PM ET****HALL B****PERIMETER**

Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation, artificial intelligence technology that is currently under clinical development. The company's ticker symbol "PINK" refers to the pink ribbons used during Breast Cancer Awareness Month.

Biotechnology**NASDAQ: PNT****Point Biopharma****Monday, May 2, 2022 | 4:00PM ET****HALL C/D**

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT is transforming precision medicine by combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 and lutetium-177.

Medical Technology

TSX: PRN, NASDAQ: PROF

Profound Medical

Monday, May 2, 2022 | 2:00PM ET

HALL B

PROFOUND

Profound Medical Corp. is a medical technology company focused on a therapeutics platform that provides the precision of real-time Magnetic Resonance Imaging combined with the safety and ablation power of directional and focused ultrasound technology for the incision-free ablation of diseased tissue.

Biotechnology

NASDAQ: RPTX

Repare Therapeutics

Monday, May 2, 2022 | 1:30PM ET

HALL C/D

REPAIRE
THERAPEUTICS

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as eight other early-stage, pre-clinical programs.

Biotechnology

TSXV: MSCL

Satellos Bioscience

Tuesday, May 3, 2022 | 2:30PM ET

HALL B



Satellos is a biotechnology company dedicated to developing lifechanging medicines that have the potential to correct a previously unrecognized root cause of degenerative muscle disorders which our scientists have identified. Satellos was established in 2018 to translate the ground-breaking discoveries of its scientific founder, Dr. Michael Rudnicki, a thought leader who discovered and has shown how muscle stem cells regulate muscle repair and growth throughout life. Satellos' lead program is focused on developing an oral therapeutic drug (i.e., a pill) to treat Duchenne muscular dystrophy where we have shown that the body's muscle stem cells don't produce enough muscle cell progenitors to keep up with the continuous damage caused by the disorder. Our drug development work offers hope for people living with Duchenne that a drug may have the potential to reset the body's innate ability to repair and grow muscle. To expand our programs, Satellos has created a proprietary discovery platform, MyoReGenX™, to identify other muscle disorders where deficits in muscle stem cell regeneration can be addressed with drug treatment.

Specialty Pharmaceutical

PRIVATE

Searchlight Pharma

Tuesday, May 3, 2022 | 2:00PM ET

HALL A



Searchlight Pharma Inc., headquartered in Montréal, is a leading Canadian-based specialty healthcare company that executes best-in class search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products. Our core products focus on women's health, urogynecology, and urology, and through our most recent purchase of ERFA Canada Inc., now also offers a diversified range of products in various therapeutic classes including endocrinology, oncology, cardiovascular, antibiotics, analgesics, and antidepressants. Our team is committed to improving people's lives by bringing the right products to market.

Medical Technology**PRIVATE****Synaptive Medical****Monday, May 2, 2022 | 10:30AM ET****HALL B****Synaptive**

Synaptive Medical Inc., a Toronto-based, global medical device and technology company solves surgical, imaging, and data challenges to improve the quality of human lives. Synaptive's integrated suite of products – bridging MRI, surgical planning, navigation, and robotic visualization – delivers novel information with automated efficiency across all stages of clinical intervention.

Healthcare Services/Digital Health**PRIVATE****The Fertility Partners****Tuesday, May 3, 2022 | 11:00AM ET****HALL C/D**

The Fertility Partners ("TFP") is a Toronto-based venture that has created a network of fertility clinics across North America. The combined group of companies includes 11 IVF clinics and over 20 locations across 6 Canadian provinces. Further growth will include additional IVF clinic acquisitions, de novo clinics and the development of adjacent services. The company is committed to being the business partner of choice for leading IVF and prenatal care practitioners with the goal of achieving world-class clinical outcomes, operational excellence and exceptional patient experiences. TFP provides partner clinics with back-office support and a collaborative, synergistic medical-scientific, professional and business environment.

Biotechnology**TSX: TH, NASDAQ: THTX****Theratechnologies****Tuesday, May 3, 2022 | 1:30PM ET****HALL B**

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We have a promising pipeline of investigational medicines in oncology and NASH and two approved medicines (EGRIFTA SV® and Trogarzo®) for people living with HIV. The Company has a sales and marketing infrastructure to commercialize its products in the U.S. and Europe. We continue to assess the market for potential product acquisitions or in-licensing transactions that would be complementary to our business and further drive future sustainable growth and value creation.

Healthcare Services/Digital Health**TSXV: THNK****Think Research****Tuesday, May 3, 2022 | 2:30PM ET****HALL C/D**

Think Research is an industry leader in delivering knowledge-based digital healthcare software solutions. The Company's focused mission is to organize the world's health knowledge so everyone gets the best care. Its evidence-based healthcare technology solutions support the clinical decision-making process, standardize care, and improve patient outcomes. For over a decade, Think's cloud-based, EMR-agnostic digital tools have empowered clinicians around the world and positively impacted millions of patients across the continuum of care – including primary physician care, acute care hospitals and surgical suites as well as community and seniors' care. Think is proud to serve as a trusted health system partner to a rapidly growing, global client base that spans five continents across more than 13,000 healthcare facilities, with a clinical audience of over 300,000 doctors, nurses and pharmacists.

Medical Technology

TSX: TMD, NASDAQ: TMDI

Titan Medical

Monday, May 2, 2022 | 3:30PM ET

TITAN MEDICAL

HALL B

Titan Medical Inc. is a medical technology company headquartered in Toronto, Ontario and with product development and regulatory affairs activities at its facility in Chapel Hill, North Carolina, is focused on enhancing robotic assisted surgery using innovative technology through a single access point. The Enos™ robotic single access surgical system is being developed with an ergonomic focus to provide a surgical experience that imitates real-life movements that surgeons demand and includes multi-articulating instruments designed to allow surgeons an increased range of motion in a confined space, with dexterity and the ability to exert the forces necessary to complete common surgical tasks. With the Enos system, Titan intends to initially pursue gynecologic surgical indications. Certain aspects of Titan's robotic assisted surgical technologies and related intellectual property have been licensed to Medtronic plc, while retaining world-wide rights to commercialize the technologies for use with the Enos system. Enos™ is a trademark of Titan Medical Inc.

Biotechnology

PRIVATE

Triumvira Immunologics

Tuesday, May 3, 2022 | 10:00AM ET

 triumvira

HALL B

Triumvira Immunologics, Inc. ("Triumvira") is a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company's proprietary T cell Antigen Coupler (TAC) technology is a robust and versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. Triumvira is headquartered in Austin, Texas with research facilities in Hamilton, Ontario.

Specialty Pharmaceutical**CSE: VPH****Valeo Pharma****Tuesday, May 3, 2022 | 11:00AM ET****HALL A**

Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory, Neurodegenerative Diseases, Oncology, and other specialty products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

Specialty Pharmaceutical**PRIVATE****Verity Pharmaceuticals****Tuesday, May 3, 2022 | 2:30PM ET****HALL A**

Verity Pharmaceuticals International Ltd. is a specialty pharmaceutical company with a primary focus on therapeutic solutions for genitourinary (GU) diseases. Verity Pharmaceuticals works with best-in-class global pharmaceutical manufacturing partners to ensure that product quality and availability is a constant deliverable. The company is also committed to supporting programs, initiatives, and organizations that help improve health, expand research opportunities and promote education within the healthcare community.

Tools**PRIVATE****Virica Biotech****Monday, May 2, 2022 | 2:30PM ET****HALL A**

Virica optimizes the manufacturing of viral medicines which allows developers to economically deploy their products at scale. Virica's Viral Sensitizer (VSE™) platform reduces production inefficiencies caused by innate anti-viral defenses in manufacturing cells. Customizable VSE cocktails substantially increase manufacturing yields and reduce the cost of goods for a range of products, including vaccines, cell and gene therapies, and anti-cancer therapies.

Healthcare Services/Digital Health**TSX: VHI****VitalHub****Tuesday, May 3, 2022 | 1:30PM ET****HALL C/D**

Software for Health and Human Services providers designed to simplify the user experience & optimize outcomes. VitalHub provides technology to Health and Human Services providers including; Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination, Patient Flow & Operational Visibility, and DOCit Mobile Apps. The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently, VitalHub serves 275+ clients across Canada, USA, UK, Australia, Qatar, and Latvia. VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka.

Healthcare Services/Digital Health**TSX: WELL****WELL Health Technologies****Tuesday, May 3, 2022 | 10:00AM ET****HALL C/D**

WELL is a technology enabled healthcare company whose overarching objective is to positively impact health outcomes to empower and support healthcare practitioners and their patients. WELL has built an innovative practitioner enablement platform that includes comprehensive end to end practice management tools inclusive of virtual care and digital patient engagement capabilities as well as Electronic Medical Records (EMR), Revenue Cycle Management (RCM) and data protection services. WELL uses this platform to power healthcare practitioners both inside and outside of WELL's own omni-channel patient services offerings. As such, WELL owns and operates Canada's largest network of outpatient medical clinics serving primary and specialized healthcare services and is the provider of a leading multi-national, multi-disciplinary telehealth offering.

Biotechnology**NASDAQ: XENE****Xenon Pharmaceuticals****Tuesday, May 3, 2022 | 11:30AM ET****HALL B**

Xenon Pharmaceuticals is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.

Biotechnology**NYSE: ZYME****Zymeworks****Monday, May 2, 2022 | 2:00PM ET****HALL C/D**

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks' second clinical candidate, ZW49, is a novel bispecific HER2-targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies.

Notes

BLOOM BURTON & CO.

The Bloom Burton team has been dedicated exclusively to the healthcare investment industry for more than a decade.

Our people have deep knowledge in medicine, science, patent and corporate law, finance, and healthcare invention, development and commercialization. We are the ideal group to help companies plan their capital market strategies, investigate the relevance of new biological pathways, consider new therapeutic indications and clinical designs, and catalogue and diligence new products or companies for acquisition.

By speaking with large companies and investors every day, we know what they are looking for.

We identify the most impactful companies for our investor network and we provide tailor-made support solutions for management teams and boards of healthcare.






**At Bloom Burton & Co.
we serve investors and
companies seeking to
make meaningful
change to the
healthcare industry.**

SERVICES

Our services help identify, cultivate and create investment opportunities in the healthcare sector on behalf of companies and investors.

From start-ups through commercial launches, we are active in all areas of the healthcare industry, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, digital health, life science tools, animal health, nutrition and wellness.



- 1. Raising Capital & Financing**
Sourcing equity and debt capital for private and public companies
- 2. M&A Advisory**
Enabling monetization through strategic transactions
- 3. Equity Research**
Influential opinions and insights on companies
- 4. Sales & Trading**
Generating returns for investors
- 5. Monetization Planning**
Scientific and business advisory services
- 6. Direct Investment**
Discretionary and principal investments
- 7. Company Creation**
Establishing and incubating new healthcare companies

Our seven business services work cohesively to accelerate monetization for both company and investor client.

SPONSORS



**Baker
McKenzie.**

Blakes

BLG
Borden Ladner Gervais



mccarthy
tetrault

RICHARDSON
Wealth | ROSEMARY HORWOOD
WEALTH



troutman
pepper

**WILSON
SONSINI**



**Thank you to our
generous sponsors**

for contributing to the
2022 Bloom Burton & Co.
Healthcare Investor Conference.

CONFERENCE INFORMATION

Company Presentations

Hall A, Hall B and Hall C/D

1-on-1 Meetings


Room 105

Keynote Address and Panel Discussions

Plenary Room 106/107

Questions or Lost and Found


Registration Area



WIFI

Network Name
Bloom Burton & Co.

Access Code
BBHIC2022



BLOOM BURTON AWARD GALA

September 29, 2022

FOUR SEASONS HOTEL
TORONTO, ONTARIO
60 YORKVILLE AVE


SPONSORSHIP INQUIRY: BBLOOM@BLOOMBURTON.COM




bloom burton & co

/accelerating returns in healthcare®

#BBHIC2022

 @bloomburton

 Bloom Burton & Co.